Leveragen announced a collaboration agreement with Daiichi Sankyo to support research efforts in advanced biologics.
Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen’s in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a shared interest in exploring innovative discovery approaches that may enable the generation and evaluation of antibody-based biologics across multiple therapeutic areas.
“We are pleased to collaborate with Daiichi Sankyo, a global leader in antibody therapeutics with deep scientific expertise and a strong commitment to innovation,” said Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen. “This collaboration reflects growing interest in next-generation in vivo discovery platforms and their potential to support diverse biologic research efforts. We look forward to working together to advance new discovery programs.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!